Paper Details

  1. Home
  2. Paper Details

[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].

Author: RuttenG E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the potential benefits and limitations of repaglinide, a new insulin secretion enhancer, for the treatment of type 2 diabetes. Repaglinide is effective in controlling blood glucose levels, particularly in patients naïve to sulfonylureas, and it has a lower incidence of hypoglycaemic symptoms. However, long-term data on its efficacy and side effects are lacking.
Paper Details　
Original Abstract of the Article :
In about 25% of type 2 diabetes patients, good diabetes control is not attainable with oral blood-glucose lowering drugs. Furthermore, in many people with diabetes the disease deteriorates, despite the use of blood-glucose lowering medication, due to the decline of the pancreatic beta cells. The dev...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11525087

データ提供：米国国立医学図書館（NLM）

Repaglinide: A Potential Breakthrough for Type 2 Diabetes

The desert of [diabetes mellitus] presents a myriad of challenges, and finding effective treatment options is a constant quest. This study focuses on [repaglinide], a novel drug with the potential to revolutionize the management of type 2 diabetes.

A New Approach to Insulin Secretion Enhancement

The researchers highlight the unique mechanism of action of repaglinide as an insulin secretion enhancer. Unlike conventional sulfonylureas, repaglinide does not continuously stimulate insulin secretion, offering a more targeted approach to blood glucose regulation.

Hope for Improved Diabetes Management

This study provides a glimmer of hope for individuals living with type 2 diabetes. The findings suggest that repaglinide may offer a valuable addition to the treatment arsenal, potentially improving blood glucose control and offering a new avenue for those who have not achieved optimal results with existing therapies.

Dr.Camel's Conclusion

As we journey through the desert of diabetes, we encounter many obstacles and challenges. This research offers a refreshing oasis—a new drug with the potential to improve the lives of individuals living with type 2 diabetes. While further research is needed, the findings are encouraging, offering a new path toward better blood glucose control and a more manageable future.
Date :
  1. Date Completed 2001-10-04
  2. Date Revised 2018-12-17
Further Info :

Pubmed ID

11525087

DOI: Digital Object Identifier

11525087

SNS
PICO Info
in preparation
Languages

Dutch

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.